KR20070005940A - 진피연조엑스의 지표성분인 헤스페리딘과베타-시클로덱스트린의 포접화합물을 함유한 한방액제 및이의 제조방법 - Google Patents
진피연조엑스의 지표성분인 헤스페리딘과베타-시클로덱스트린의 포접화합물을 함유한 한방액제 및이의 제조방법 Download PDFInfo
- Publication number
- KR20070005940A KR20070005940A KR1020050059631A KR20050059631A KR20070005940A KR 20070005940 A KR20070005940 A KR 20070005940A KR 1020050059631 A KR1020050059631 A KR 1020050059631A KR 20050059631 A KR20050059631 A KR 20050059631A KR 20070005940 A KR20070005940 A KR 20070005940A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- herbal
- hesperidin
- cyclodextrin
- beta
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
조성성분(75mL) | 비교예 4 | 실시예 2 | 실시예 3 | 실시예 4 | 실시예 5 | 실시예 6 |
인삼건조엑스 | 20mg | 20mg | 20mg | 20mg | 20mg | 20mg |
건강틴크 | 225㎕ | 225㎕ | 225㎕ | 225㎕ | 225㎕ | 225㎕ |
계피틴크 | 250㎕ | 250㎕ | 250㎕ | 250㎕ | 250㎕ | 250㎕ |
진피연조엑스 | 20mg | 20mg | 20mg | 20mg | 20mg | 20mg |
DL-염산카르니틴 | 150mg | 150mg | 150mg | 150mg | 150mg | 150mg |
안식향산나트륨 | 75mg | 75mg | 75mg | 75mg | 75mg | 75mg |
고과당 | 10,000mg | 10,000mg | 10,000mg | 10,000mg | 10,000mg | 10,000mg |
구연산 | 80mg | 80mg | 80mg | 80mg | 80mg | 80mg |
구연산나트륨 | 40mg | 40mg | 40mg | 40mg | 40mg | 40mg |
β-시클로덱스트린 | - | 0.1g | 0.25g | 0.5g | 1.0g | 1.8g |
Claims (5)
- 베타-시클로덱스트린과 진피연조엑스의 지표성분인 헤스페리딘과의 포접체를 함유함을 특징으로 하는 진피연조엑스를 함유한 한방 액제 조성물.
- 제 1항에 있어서, 상기 액제 조성물은 베타-시클로덱스트린을 총 액제 조성물 부피 대비 약 0.01 내지 2 w/v%를 함유하는 한방 액제 조성물.
- 제 2항에 있어서, 상기 액제 조성물은 베타-시클로덱스트린을 총 액제 조성물 부피 대비 약 0.60~1.35 w/v%를 함유하는 한방 액제 조성물.
- 진피연조엑스를 함유한 한방 원료생약에 추출 용매를 가하여 추출하여 생약 추출물을 얻고 상기 생약 추출물을 여과한 후, 이 추출 여과물을 농축기를 사용하여 1/5 내지 1/1로 농축하여 연조엑스를 조제하고 여기에 약 0.1 내지 1.85 중량비(w/v%)의 베타-시클로덱스트린을 가한 다음, 정제수를 가하여 90℃ 이상에서 약 30분 내지 2시간 동안 가온 용해시킴을 특징으로 하는, 제 1항의 헤스페리딘 포접체를 함유한 한방 액제 조성물을 제조하는 방법.
- 진피연조엑스를 함유한 한방 원료생약에 원료 중량의 약 1 내지 20배 부피 분량의 정제수 또는 추출 용매를 가하여 80 내지 100℃에서 1 내지 12시간 동안 추출하여 생약 추출물을 얻는 제 1단계; 상기 생약 추출물을 200 내지 500 메쉬 및 약 0.5 내지 2 ㎛의 여과지에 통과시켜 추출 여과물을 얻는 제 2단계; 상기 추출 여과물을 농축기를 사용하여 1/5 내지 1/1로 농축하여 연조엑스를 얻는 제 3단계; 상기 농축된 연조엑스에 총 액제 조성물 부피 대비 약 0.01 내지 2 w/v%의 베타-시클로덱스트린을 정제수 적당량에 가하여 90 ℃ 이상에서 가온 용해시키고 혼합시켜 추출 여과물 내에서 헤스페리딘 포접화합물을 반응시키는 제 4단계; 상기 액제를 멸균 처리하고 정제수를 가하여 최종 액제 조성물을 제조하는 제 5단계 공정을 포함함을 특징으로 하는, 제 1항의 헤스페리딘 포접체를 함유한 한방 액제 조성물을 제조하는 방법.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050059631A KR100736901B1 (ko) | 2005-07-04 | 2005-07-04 | 진피연조엑스의 지표성분인 헤스페리딘과베타-시클로덱스트린의 포접화합물을 함유한 한방액제 및이의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020050059631A KR100736901B1 (ko) | 2005-07-04 | 2005-07-04 | 진피연조엑스의 지표성분인 헤스페리딘과베타-시클로덱스트린의 포접화합물을 함유한 한방액제 및이의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070005940A true KR20070005940A (ko) | 2007-01-11 |
KR100736901B1 KR100736901B1 (ko) | 2007-07-06 |
Family
ID=37871270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050059631A KR100736901B1 (ko) | 2005-07-04 | 2005-07-04 | 진피연조엑스의 지표성분인 헤스페리딘과베타-시클로덱스트린의 포접화합물을 함유한 한방액제 및이의 제조방법 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100736901B1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112516331A (zh) * | 2020-12-16 | 2021-03-19 | 广州白云山汉方现代药业有限公司 | 一种提高橙皮苷水溶性及生物利用度的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3060227B2 (ja) | 1989-06-03 | 2000-07-10 | 株式会社林原生物化学研究所 | α―グリコシル ヘスペリジンとその製造方法並びに用途 |
-
2005
- 2005-07-04 KR KR1020050059631A patent/KR100736901B1/ko active IP Right Grant
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112516331A (zh) * | 2020-12-16 | 2021-03-19 | 广州白云山汉方现代药业有限公司 | 一种提高橙皮苷水溶性及生物利用度的方法 |
CN112516331B (zh) * | 2020-12-16 | 2023-05-23 | 广州白云山汉方现代药业有限公司 | 一种提高橙皮苷水溶性及生物利用度的方法 |
Also Published As
Publication number | Publication date |
---|---|
KR100736901B1 (ko) | 2007-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20180326090A1 (en) | Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use | |
JP6322289B2 (ja) | Hdlコレステロール値を上昇させることによって疾病を治療かつ/または予防する、メチルシクロデキストリンをベースとする組成物 | |
US7683040B2 (en) | Intranasal formulation of rotigotine | |
JP2007536228A (ja) | セルトラリンおよびスルホアルキルエーテルシクロデキストリンを含有するテイストマスク製剤 | |
US20060120967A1 (en) | Solution forms of cyclodextrins for nasal or throat delivery of essential oils | |
JP5103476B2 (ja) | シクロデキストリン・ドセタキセルの包接体を含む薬物組成物及びその製造方法 | |
CN104704007A (zh) | 烷基化环糊精组合物及其制备和使用方法 | |
JPS61500788A (ja) | 水に不安定なまたは僅かに溶解性の薬物を含有する医薬調製物およびその製造方法 | |
HU230456B1 (hu) | Aripiprazol orális oldatai | |
JP5021305B2 (ja) | 水溶性ジテルペンの調製方法およびその適用 | |
AU2018202482A1 (en) | Racecadotril liquid compositions | |
CA2519418A1 (en) | New injectable formulations containing progesterone | |
EA022751B1 (ru) | Жидкая композиция деферипрона с замаскированным вкусом | |
KR20110015445A (ko) | 아미노시클로헥산 유도체 및 시클로덱스트린의 복합체를 포함하는 제약 조성물 | |
CN102697711A (zh) | 地氯雷他定口服液体制剂及其制备方法 | |
CN113133512A (zh) | 一种含柚皮苷的饮料及其制备方法 | |
KR100736901B1 (ko) | 진피연조엑스의 지표성분인 헤스페리딘과베타-시클로덱스트린의 포접화합물을 함유한 한방액제 및이의 제조방법 | |
EP0490193A1 (de) | Komplexe des aktiven Enantiomers des Ibuprofens mit Cyclodextrin | |
US6303157B1 (en) | Extracts of kava-kava | |
RU2712264C2 (ru) | Состав для инъекций на основе силибина и способ его получения | |
CN113226285A (zh) | 布雷那兰的口服配制品 | |
KR100675081B1 (ko) | 아세틸시스테인 함유 경구용 제제 | |
JPS61268627A (ja) | 水性液剤の製法 | |
KR20120082061A (ko) | 안정하고 불쾌한 맛이 차폐된 덱시부프로펜을 함유한 투명한 시럽 조성물 | |
EP0449722B1 (fr) | Nouveaux complexes de l'acide tiaprofénique ou de ses esters insolubles ou partiellement solubles avec les cyclodextrines ou leurs dérivés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
G170 | Publication of correction | ||
FPAY | Annual fee payment |
Payment date: 20121128 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20131127 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20141208 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20180104 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20190103 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20200107 Year of fee payment: 14 |